Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (3): 262-265.doi: 10.35541/cjd.20220659

• Special Article • Previous Articles     Next Articles

Reasonable selection of antiviral agents for herpes zoster

Wang Xingwang, Yang Huilan   

  1. Department of Dermatology, General Hospital of Southern Theater Command of PLA, Guangzhou 510010, China
  • Received:2022-09-16 Revised:2022-12-30 Online:2023-03-15 Published:2023-03-06
  • Contact: Yang Huilan

Abstract: 【Abstract】 Antiviral treatment is the core part in the treatment of herpes zoster. Based on the latest studies, consensus and guidelines, this article aims to provide a basis and reference for clinicians to make a reasonable choice of types and doses of antiviral agents. Valacyclovir, a precursor of acyclovir with high oral bioavailability and great convenience of administration, is generally the first choice of oral antiviral agents; for some special cases, such as immunocompromised patients, intravenous drips of acyclovir should be selected when appropriate. Brivudine is often a better choice for patients with severe renal insufficiency; famciclovir or other antiviral agents should be considered for patients resistant to acyclovir; for immunocompromised patients resistant to acyclovir, intravenous drips of foscarnet sodium can be an option. Oral antiviral agents should be administered at adequate doses. Selecting appropriate antiviral agents and their doses can effectively relieve acute symptoms of patients and reduce the probability of postherpetic neuralgia.

Key words: Herpes zoster, Antiviral agents, Acyclovir, Valacyclovir, Famciclovir, Brivudine, Foscarnet sodium, Dosage, Treatment course